Seres Therapeutics, Inc. announced that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th, 2024, following David Arkowitz?s retirement. Prior to joining Seres, she served in executive positions with Evelo Biosciences, Centessa Pharmaceuticals, Palladio Biosciences and Realm Therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9199 USD | -0.49% | -10.69% | -34.29% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.29% | 140M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Seres Therapeutics Appoints Marella Thorell as Executive Vice President